Research Reveals How Aspirin Can Help People with Head and Neck Cancer


Latest research reveals that regular usage of the non-steroidal anti-inflammatory drugs like Aspirin could be linked with the longer survival of some patients with head and neck cancer.

A team of researchers recently proposed how the recent clinical trials could lead to testing the overall effectiveness as well as the safety of the NSAIDs (non-steroidal anti-inflammatory) drugs like Aspirin in the treatment of head and neck cancer.  The team of researchers suggests that they have observed the effect of the NSAIDs in reducing prostaglandin E2.  Prostaglandin E2 is a molecule that is known for promoting inflammation.  A paper was recently released by the team of researchers in the journal named “Journal of Experimental Medicine.”

Head and neck cancers are associated with tumors developing in the regions including nose, sinus, throat, mouth, and larynx.  In most of the typical cases, the tumors in the head & neck region tend to rise up in the thin squamous cells that are known for forming the lining of the tissue surfaces.  This is the reason why these tumors are named as HNSCCs –Head, and Neck Squamous Cell Carcinomas.

In the USA, around 4 percent of the people are known to have HNSCCs amongst other forms of cancers.  However, the cancers associated with HNSCCs are also known to have the least survival rates for the patients amongst all other cancers.  The major risks linked with HNSCCs are increased consumption of tobacco, infection with HPV (Human Papillomavirus), alcohol consumption, and exposure to sunlight.

Recent research reveals that regular use of Aspirin can reduce the chances of developing HNSCCs.   The latest research also links the overall effectiveness of other NSAIDs towards ensuring the longer survival of those having head and neck cancer.  The regular utilization of the NSAIDs was found to create no major difference in people having HNSCC than those who did not have PIK3CA gene alterations.  The team of researchers has defined the regular usage of the NSAIDs to be around twice a week for at least six months or even longer.

Professor Jennifer R. Grandis – MD at the University of California in the Department of Otolaryngology, says, “The current study is the first study that helps in demonstrating the fact that regular utilization of the NSAIDs can prove advantageous significantly in the patients having PIK3CA-altered Head and Neck cancer.”